Drug evaluation: LB-80380--a novel phosphonate nucleoside for the potential treatment of HBV infection.
LG Life Sciences Ltd (formerly LG Chem Ltd), in collaboration with Anadys Pharmaceuticals Inc, is developing LB-80380 (PMCDG dipivoxil), an orally available lead compound in a series of phosphonate nucleotides, for the potential treatment of hepatitis B virus infection. In April 2003, phase II trials were initiated, the results of which were reported in February 2006. LB-80380 is the prodrug of LB-80317 (PMCDG), another compound from this series.
Papatheodoridis
George V
GV
2nd Department of Internal Medicine, Athens University Medical School, Hippokration General Hospital of Athens, 114 Vas Sofias Avenue, Athens 11527, Greece. gepapath@med.uoa.gr
Manolakopoulos
Spilios
S
D000818:Animals; D000998:Antiviral Agents / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006147:Guanine / Q000031:analogs & derivatives* / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use; D006509:Hepatitis B / Q000188:drug therapy*; D006801:Humans; D063065:Organophosphonates / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*
C487369:((1-((2-amino-9H-purin-9-yl)methyl)cyclopropyl)oxy)methylphosphonic acid dipivoxyl; D000998:Antiviral Agents; D063065:Organophosphonates; D006147:Guanine